Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
34.96
+0.88 (2.58%)
At close: Aug 8, 2025, 4:00 PM
34.56
-0.40 (-1.14%)
After-hours: Aug 8, 2025, 7:18 PM EDT
Paramount Global Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$228,892
Profits / Employee
-$113,708
Market Cap
3.84B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,869 | -306 | -14.07% |
| Dec 31, 2023 | 2,175 | 139 | 6.83% |
| Dec 31, 2022 | 2,036 | 85 | 4.36% |
| Dec 31, 2021 | 1,951 | 757 | 63.40% |
| Dec 31, 2020 | 1,194 | 502 | 72.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZLAB News
- 1 day ago - Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 4 weeks ago - Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 - Business Wire
- 5 weeks ago - Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer - Business Wire
- 2 months ago - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire
- 2 months ago - Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Business Wire
- 2 months ago - Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire
- 2 months ago - Zai Lab Announces Participation in Investor Conferences in June 2025 - Business Wire